Home
BioMarin

BioMarin Market Share Analysis for August 2026

Healthcare professionals and patients may report information on adverse events by submitting a form or contacting us by email or fax.

Health > Biotechnology and Pharmaceuticals

Domainbiomarin.com

Year Founded1997

Employees1001 - 5000

Annual Revenue> $1B

BioMarin

BioMarin (including company regionals)

biomarin.com

See more website traffic and engagement information

BioMarin Revenue up to August 2026 is > 1B

revenue generated by BioMarin top domains

BioMarin top domains revenue over 3 years

Revenue for BioMarin top domains

biomarin.com> 1B

See more with Sales Intelligence

BioMarin Stock price in August 2026

BioMarin stock is traded under the ticker #BMRN. Below you can review BioMarin stock performance in the past 12 months up to August 2026

Total visits to BioMarin's top domains

Understand BioMarin market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

biomarin.com109.2K

See more with Sales Intelligence

Avg. visit duration in BioMarin's top domains

Analyze BioMarin engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

biomarin.com00:00:32

See more with Sales Intelligence

Avg. pageviews on BioMarin's top domains

See how BioMarin keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

biomarin.com1.87

See more with Sales Intelligence

BioMarin top competitors by domain

Top similar sites in August 2026, ranked by their affinity

biogen.comCompany NameBiogenEmployees5001 - 10000HQUnited States, Massachusetts, CambridgeAnnual revenue> $1BTotal visits162.5KHealth > Medicine

Top technologies used by BioMarin

These are the website technologies, by industry, used by BioMarin top domains

Payment & Currencies (23)

PayPal

Widget (9)

Twemoji

Advertising (4)

Google Adsense

Social (4)

Instagram

More Technologies

10

See all

News & Signals from BioMarin

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsCASI Pharmaceuticals, Inc. sold assets to BioMarin Pharmaceutical Inc. in the amount of $5.9M on Aug 31st '26.CASI Pharmaceuticals, Inc. (CASIF) reported that it has sold its equity interests in Alesta Therapeutics B.V. to BioMarin Pharmaceutical Inc. under a Share Purchase Agreement, with the transaction closing on August 31, 2026.

NewsBioMarin Pharmaceutical Inc. identified as competitor of AstraZeneca on Aug 18th '26.BioMarin Pharmaceutical has agreed to acquire Alesta Therapeutics for $275 million upfront, a deal that builds out BioMarin's rare bone disease franchise and sets it up to compete with AstraZeneca in that market; BMRN traded at 68.15, up 2.27%, as of 16:33 GMT on 18 August 2026.

NewsBioMarin Pharmaceutical Inc. is planning to acquire Alesta Therapeutics.BioMarin Pharmaceutical Inc. has entered into a definitive agreement to acquire Alesta Therapeutics to gain Alesta's lead clinical-stage asset, ALE1, with Alesta shareholders set to receive an upfront payment of $275 million plus up to $215 million in subsequent payments upon achievement of certain development and regulatory milestones.[4]